Pfizer Inc. (NYSE:PFE) Shares Sold by Harbour Investments Inc.

Harbour Investments Inc. lowered its position in Pfizer Inc. (NYSE:PFE) by 14.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 62,692 shares of the biopharmaceutical company’s stock after selling 10,341 shares during the period. Harbour Investments Inc.’s holdings in Pfizer were worth $1,663,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Envestnet Portfolio Solutions Inc. lifted its holdings in Pfizer by 3.6% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 600,366 shares of the biopharmaceutical company’s stock valued at $15,928,000 after purchasing an additional 20,991 shares in the last quarter. one8zero8 LLC purchased a new position in Pfizer in the 4th quarter valued at $1,656,000. Van Strum & Towne Inc. lifted its holdings in Pfizer by 5.5% in the 4th quarter. Van Strum & Towne Inc. now owns 69,684 shares of the biopharmaceutical company’s stock valued at $1,849,000 after purchasing an additional 3,655 shares in the last quarter. Brandes Investment Partners LP lifted its holdings in Pfizer by 16.8% in the 4th quarter. Brandes Investment Partners LP now owns 6,708,164 shares of the biopharmaceutical company’s stock valued at $177,968,000 after purchasing an additional 962,837 shares in the last quarter. Finally, Zevin Asset Management LLC lifted its holdings in Pfizer by 46.0% in the 4th quarter. Zevin Asset Management LLC now owns 16,182 shares of the biopharmaceutical company’s stock valued at $429,000 after purchasing an additional 5,095 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Citigroup reduced their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Wednesday, March 12th. Finally, UBS Group reduced their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Up 1.3 %

Shares of PFE opened at $26.07 on Tuesday. The firm has a market cap of $147.72 billion, a P/E ratio of 18.49, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company’s 50-day moving average price is $26.22 and its 200 day moving average price is $27.10. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.10 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.